MEREO BIOPHARMA GROUP PLC (MREO) Return on equity 2022–2025
MEREO BIOPHARMA GROUP PLC (MREO) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
102.4%FY2025 · since FY2022: -82.1% → 102.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 102.4% | +31.4 pp |
| FY2024 | 70.9% | +12.6 pp |
| FY2023 | 58.3% | +140.4 pp |
| FY2022 | -82.1% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice